Eupraxia Pharmaceuticals (EPRX) Income towards Parent Company (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Income towards Parent Company for 4 consecutive years, with $12.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 87.11% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $11.0 million (up 1427.9% YoY), while the FY2025 annual figure was -$38.6 million, down 49.96% from the prior year.
• Income towards Parent Company climbed to $12.7 million in Q1 2026 per EPRX's latest filing, from -$16.7 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $12.7 million in Q1 2026 and bottomed at -$16.7 million in Q4 2025.
• Historically, Income towards Parent Company has averaged -$502679.5 across 4 years, with a median of -$412974.5 in 2023.
• Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 255.13% — and 2025, when it jumped 245.51%.
• Eupraxia Pharmaceuticals' Income towards Parent Company stood at -$4.7 million in 2023, then tumbled by 59.5% to -$7.5 million in 2024, then slumped by 121.9% to -$16.7 million in 2025, then jumped by 175.72% to $12.7 million in 2026.
• Business Quant data shows EPRX's Income towards Parent Company at $12.7 million in Q1 2026, -$16.7 million in Q4 2025, and $6.4 million in Q3 2025.